The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big Ten Cancer Research Consortium BTCRC GU16-043.
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; TTC Oncology
Travel, Accommodations, Expenses - Newlink Genetics
 
Eric A. Singer
Research Funding - Astellas Medivation
 
Ryan Ross
No Relationships to Disclose
 
Monika Joshi
Research Funding - AstraZeneca (Inst); Eisai (Inst); Pfizer (Inst)
 
Michael Abern
No Relationships to Disclose
 
Rohan Garje
No Relationships to Disclose
 
Joseph J. Park
No Relationships to Disclose
 
Ilona Kryczek
No Relationships to Disclose
 
Weiping Zou
No Relationships to Disclose
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck